Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapie

Rizzo, M., Montalto, G., Al-Rasadi, K. (2014). Treatment options for managing atherogenic dyslipidemia and fatty liver disease. EXPERT OPINION ON PHARMACOTHERAPY, 15(8), 1065-1068 [10.1517/14656566.2014.902051].

Treatment options for managing atherogenic dyslipidemia and fatty liver disease

RIZZO, Manfredi;MONTALTO, Giuseppe;
2014-01-01

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapie
2014
Rizzo, M., Montalto, G., Al-Rasadi, K. (2014). Treatment options for managing atherogenic dyslipidemia and fatty liver disease. EXPERT OPINION ON PHARMACOTHERAPY, 15(8), 1065-1068 [10.1517/14656566.2014.902051].
File in questo prodotto:
File Dimensione Formato  
151 EOP 2014 proofs.pdf

Solo gestori archvio

Dimensione 157.97 kB
Formato Adobe PDF
157.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/98967
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact